Financial Data and Key Metrics Changes - Total revenue for Q3 Fiscal 2026 was $120.3 million, representing a 13% year-over-year increase [11] - Adjusted EBITDA reached $29.1 million, an increase of $19 million year-over-year and $7 million quarter-over-quarter, with an all-time high adjusted EBITDA margin of 24% [11] - Net income was $4.3 million, marking the second consecutive quarter of positive net income [12] - Cash and cash equivalents at the end of the quarter were $106.4 million, up from $98.3 million in the prior quarter [14] - Operating cash flow was $15.5 million, up $9.7 million year-over-year, and free cash flow was $8.8 million, up $7.2 million year-over-year [14] Business Line Data and Key Metrics Changes - Average healthcare services clients (AHSCs) increased to 4,520, up by 53 from the prior quarter [11] - Total revenue per AHSC was $26,622, a 6% increase year-over-year [12] Market Data and Key Metrics Changes - The company expects to add approximately 80 AHSCs annually through the AccessOne acquisition, which manages a portfolio of approximately $450 million [16] - The blended take rate for AccessOne's managed portfolio averages 4%-12% depending on the provider type and program mix [16] Company Strategy and Development Direction - The company is focusing on provider financing and healthcare provider marketing as new growth areas [6][8] - The acquisition of AccessOne is seen as a significant growth lever to enhance cash flow for healthcare providers [8] - The company aims to leverage its existing relationships and infrastructure to engage healthcare providers and life sciences partners effectively [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining growth and enhancing stakeholder value through emerging products [5] - The updated revenue outlook for fiscal 2026 is projected to be between $479 million and $481 million, reflecting a contribution from AccessOne [17] - For fiscal 2027, the company anticipates revenue in the range of $545 million to $559 million, with adjusted EBITDA expected to be between $125 million and $135 million [19] Other Important Information - The company has achieved positive operating cash flow and free cash flow for five consecutive quarters [14] - The AccessOne acquisition was funded with approximately $53 million in cash and a $110 million secured bridge loan [15] Q&A Session Summary Question: Growth potential for AccessOne - Management indicated that AccessOne's product needs investment before it can be offered to the majority of existing clients, with plans to invest in go-to-market strategies [22][23] Question: Financing and market conditions - Management is actively looking to refinance the bridge loan and is optimistic about market demand for financing solutions [26][27] Question: Core growth expectations for fiscal 2027 - Management expects network solutions to grow the fastest, followed by payment processing and subscription services [31][32] Question: HCP marketing initiative - The company has started selling the HCP marketing offering to select clients and anticipates it will generate incremental revenue [39][40] Question: Updated fiscal 2026 guidance - Management clarified that the updated guidance reflects a more measured approach to network solutions due to market fluidity [42][45] Question: AccessOne's funded and unfunded models - Management highlighted AccessOne's flexibility in offering various funding models to meet client needs and expects to learn which offerings resonate best over time [47][49]

Acquisition - Phreesia acquired AccessOne for $160 million in cash, funded by a mix of cash and debt [11, 12] - The acquisition extends Phreesia's reach into provider financing, addressing a $74 billion market [13, 15] - AccessOne's results are not included in the Q3 FY2026 presentation [6] Financial Performance - Total revenue for Q3 FY2026 was $120 million, a 13% year-over-year increase [19] - Adjusted EBITDA for Q3 FY2026 was $29 million, a 198% year-over-year increase [19] - Total revenue per AHSC for Q3 FY2026 was $26600, a 6% year-over-year increase [19] Outlook - FY2026 total revenue is projected to be between $479 million and $481 million, with Adjusted EBITDA between $99 million and $101 million [51] - The company anticipates approximately 4515 AHSCs for FY2026 [51] - FY2027 total revenue is projected to be between $545 million and $559 million, with Adjusted EBITDA between $125 million and $135 million [53, 54]

ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, Inc. (NYSE: PHR) ("Phreesia†or the "Company") announced financial results today for the fiscal third quarter ended October 31, 2025. "I am very proud of our team's strong execution in the fiscal third quarter, which is reflected throughout this letter from our revenue and profit results to product updates and client stories,†said CEO and Co- Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the ...

Core Insights - HealthLynked Corp. has appointed Duncan McGillivray as the new Chief Operating Officer, bringing over 30 years of executive leadership experience in healthcare, technology, and finance [1][2][3] Group 1: Executive Appointment - Duncan McGillivray will drive operational scale-up, support national payer and employer partnerships, and lead capital formation as HealthLynked aims to uplist to the Nasdaq Capital Market [1][2] - McGillivray's extensive background includes senior roles in healthcare systems, fintech, and capital project advisory, positioning him to accelerate HealthLynked's growth trajectory [2][3] Group 2: Strategic Focus - McGillivray will oversee HealthLynked's capital-raising strategy and investor engagement programs to support the planned Nasdaq uplisting in 2026 [2][3] - His role will also involve guiding the rollout of ARI, HealthLynked's patented AI healthcare guide, and participating in nationwide initiatives aimed at enhancing interoperability and AI-driven healthcare [4][5] Group 3: Company Vision - HealthLynked aims to enhance healthcare through personalized care management, connecting patients with providers for improved outcomes and reduced costs [5][7] - The company's platform integrates AI-driven insights and telehealth services, empowering effective care coordination and delivering savings on healthcare services [7]

Group 1 - The core viewpoint is that technology remains the strongest driving force, with significant improvements in self-reliance and core technology breakthroughs in key areas, leading to deep integration of technological and industrial innovation [1] - The AI industry chain shows a consistent performance advantage in the computing power segment for three consecutive quarters, indicating a clear trend of industrial prosperity, with the computing power sector being the highest and most sustainable profit growth area [1] - There is a substantial demand gap for computing power in the future, and the high prosperity will continue to drive profits upward, with domestic computing power chains expected to have greater potential as the Sino-US computing power competition intensifies [1] Group 2 - The energy storage chain is experiencing unexpected upward prosperity, likely to continue due to increased power consumption driven by AI computing power, which boosts the overall prosperity of the energy storage chain [1] - The storage sector is entering a long-term upward cycle, supported by supply-demand and structural contradictions that sustain long-term prosperity in storage [1] - The Science and Technology Innovation Board 100 ETF (588120) tracks the Science and Technology Innovation 100 Index (000698), which has a daily fluctuation of 20%, reflecting the overall performance of 100 mid-cap securities in the Science and Technology Innovation Board [1]

Summary of the 2026 Hospital Outlook Survey Industry Overview - The survey focuses on the US healthcare industry, specifically the hospital sector, and provides insights into capital expenditures, utilization trends, and the impact of macroeconomic factors on hospital operations [1][2]. Key Insights Utilization Trends - **Utilization Growth Expectations**: 52% of hospital executives anticipate utilization growth in 2026 to be above 2025 levels, a decrease from 55% in the previous year [7][19]. - **Outpatient vs. Inpatient**: 56% expect outpatient utilization growth to exceed 2025 levels, while 41% expect inpatient utilization growth to increase, up from 34% last year [11][19]. - **Elective Procedures**: 54% expect elective procedures to grow above or in line with 2025 levels, down from 64% last year [16][19]. Capital Expenditures (CapEx) - **CapEx Growth**: Hospital capital spending is projected to increase by 4.1% in 2026, consistent with the 4.0% growth reported in 2025 [7][45]. - **Investment Priorities**: Hospitals are likely to increase spending on bedside patient monitoring, bedside pumps, and operating room (OR) suite equipment [16][45]. - **Impact of OBBBA**: The One Big Beautiful Bill Act (OBBBA) may lead to conservative spending due to anticipated reimbursement pressures [49][46]. Robotics and Technology - **Robotic Systems**: 96% of hospitals currently utilize surgical robotic systems, with Intuitive Surgical maintaining a leading position in soft-tissue robotics [90][91]. - **Orthopedic Robotics Demand**: 49% of respondents expect to purchase orthopedic robotic systems, with Stryker's MAKO being the most favored option [7][8]. - **IT Investments**: Hospitals are prioritizing IT investments, particularly in AI (66% expect to increase spending) and cybersecurity (65%) [80][81]. Value-Based Care (VBC) - **Revenue Tied to VBC**: The average revenue tied to VBC arrangements is approximately 19%, down from 22% last year, although interest in establishing VBC partnerships has increased [34][35]. Challenges and Concerns - **Reimbursement Pressure**: 34% of executives cite reimbursement pressure as the biggest challenge for hospitals in the coming year, an increase from 25% last year [58][59]. - **Labor Costs**: Labor cost inflation remains a significant concern, with 18% of respondents identifying it as a major challenge [58][59]. Future Outlook - **Purchasing Intentions**: Despite economic uncertainties, over 70% of hospitals plan to consider purchasing new equipment across various categories in the next two years [62][64]. - **Investment in ASCs**: 57% of respondents expect to increase investments in Ambulatory Surgery Centers (ASCs) over the next year, reflecting a shift towards outpatient care [18][19]. Additional Insights - **AI Utilization**: Hospitals are increasingly leveraging AI for tasks such as medical record analysis (56%) and clinical imaging analysis (52%), with larger hospitals showing a higher propensity to adopt these technologies [81][88]. - **Market Dynamics**: The survey indicates a stable payor mix for 2026, with commercial insurers and Medicare making up approximately 70% of the mix [12][27]. This comprehensive survey provides a detailed outlook on the hospital sector, highlighting trends in utilization, capital spending, and the evolving landscape of healthcare technology and reimbursement challenges.

Beijing, China, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (NASDAQ: PTHL) (“Pheton” or the “Company”), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today announced the successful completion of its acquisition of 51% of the total outstanding shares of iTonic Corporation (the “Target”), a U.S.-based integrated home health AI company that combines AI, medical device automation, and easier access to clinical exper ...

Core Insights - Tempus AI operates at the intersection of clinical genomics and AI-driven insights, with significant revenue growth and improving margins in 2024, attracting investor attention on its earnings potential [1][8]. Company Overview - Tempus AI is a healthcare technology company focused on precision medicine through AI, aggregating multimodal clinical and lab data to provide solutions to various stakeholders [2]. - The company’s operations include Genomics, which covers oncology and hereditary testing, and Data and services, which commercialize de-identified datasets and analytics [2]. Sales Performance - In 2024, Tempus generated approximately $693 million in revenue, a 30% increase from 2023, with Genomics contributing about $451.7 million (65%) and Data and services about $241.6 million (35%) [3][8]. - Revenue is projected to reach $1.6 billion by 2026, driven by increased testing volumes and scaled data products [3][8]. Profitability and Earnings Quality - The company achieved non-GAAP profitability in Q3, with expectations for narrowing EPS losses through 2026, despite remaining negative on a GAAP basis [4][8]. - The trajectory indicates a loss of 17 cents per share in 2027, following deeper losses in 2024 and narrower losses in 2025 [4]. Investor Outlook - Recent performance has shown solid execution, with a 31% EPS surprise and a 2.4% sales surprise, which may bolster investor confidence [5]. - The stock currently holds a Zacks Rank 3-Hold, indicating a neutral near-term outlook, with momentum performing better than valuation and growth [6]. Competitive Landscape - Key competitors include Exact Sciences and Guardant Health, which operate in adjacent markets and influence competitive dynamics in precision oncology solutions [11].

Core Insights - Several companies have shown significant price movements, attracting investor attention, including Aclarion, Inc., Aeva Technologies, Polyrizon Ltd., SMX, and Synchronoss Technologies [1] Company Summaries - **Aclarion, Inc. (NASDAQ:ACONW)**: The stock price surged to $0.11, reflecting a 184.97% increase, driven by a trading volume of 369,174, focusing on healthcare technology solutions for degenerative pain biomarkers [2][7] - **Polyrizon Ltd. (NASDAQ:PLRZ)**: The stock price rose to $13.95, marking a 96.76% gain, with a trading volume of 23,290,576, attributed to its innovative nasal sprays aimed at blocking viruses and allergens, and a pivotal manufacturing milestone [3][7] - **SMX (Security Matters) Public Limited Company (NASDAQ:SMX)**: The stock price increased to $102.45, a 75.16% rise, with a trading volume of 3,851,727, reflecting market confidence in its proprietary marker system and blockchain technology for brand protection [4][7] - **Synchronoss Technologies, Inc. (NASDAQ:SNCR)**: The stock price climbed to $8.71, a 64.34% increase, with a trading volume of 1,740,890, following a definitive acquisition agreement by Lumine Group for approximately $116.4 million, enhancing its portfolio in communications and media software [5][7] Market Environment - The recent price movements indicate a dynamic market environment where technological advancements and innovative solutions are crucial in driving investor interest and stock performance [6]

Core Insights - MEDIROM Healthcare Technologies Inc. has announced a distributor agreement with TD SYNNEX K.K. to enhance the distribution of its health-tech products, specifically the MOTHER Bracelet and REMONY system [2][3][4] Company Overview - MEDIROM MOTHER Labs Inc. is a subsidiary of MEDIROM Healthcare Technologies, focusing on health-tech solutions, including the development and sales of the MOTHER Bracelet and the REMONY health monitoring system [13] - The MOTHER Bracelet is a unique 24/7 recharge-free smart tracker that measures key health metrics such as heart rate, calories burned, body temperature, step count, and sleep without needing to be removed for charging [7][10] Partnership Initiatives - The collaboration with TD SYNNEX aims to leverage its extensive sales network and expertise in IT product distribution to accelerate the nationwide expansion of MEDIROM's health management solutions [3][4] - TD SYNNEX has a proven track record in the Japanese market for successfully distributing smart trackers, which will benefit the partnership [4] Product Features - The MOTHER Bracelet utilizes advanced technology to generate electricity from temperature differences, ensuring continuous operation without recharging [7] - The REMONY system integrates the MOTHER Bracelet with a dedicated gateway for real-time health monitoring and data synchronization, addressing common issues of data loss during device charging [10][12] - The system is customizable for various industries, including elder care and health monitoring for night shift workers, enhancing its applicability [12]